MERZ-THERAPEUTICS
Merz Therapeutics announces today the successful acquisition of INBRIJA® (levodopa inhalation powder) and (F)AMPYRA® (fampridine), and related assets from Acorda Therapeutics, Inc. AMPYRA® (dalfampridine) is Food and Drug Administration (FDA) approved in the U.S. and commercialized as FAMPYRA in the European Union and other territories throughout the world. This transaction was conducted through a court-structured 363 sale under the U.S. Bankruptcy Code. The completion of this deal, valued at USD 185 million in cash, bolsters Merz Therapeutics’ market position by enhancing offerings for people living with Parkinson’s disease and expanding into the multiple sclerosis (MS) space.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240710459851/en/
“The addition of INBRIJA and (F)AMPYRA to the treatment portfolio underlines Merz Therapeutics’ global Pivot for Growth strategy to both evolve the current portfolio and achieve critical scale and global reach,” said Stefan König, CEO of Merz Therapeutics. “Merz Therapeutics is well poised to build on what we have accomplished in the specialty neurology space, strengthening our market position in Parkinson’s disease and expanding into the MS segment. This deal demonstrates Merz Therapeutics’ interest and ability to acquire assets that will deliver greater, sustainable outcomes for more people living with neurological disorders.”
INBRIJA and (F)AMPYRA are projected to immediately add topline revenue which will enhance Merz Therapeutics’ ability to accelerate clinical development of its existing and new assets. Its U.S. business is forecasted to contribute more than 75% of INBRIJA’s and (F)AMPYRA’s total global revenues over the next 10 years. Additionally, the company expects the U.S. workforce to increase by more than 50%.
INBRIJA is a significant advancement for people living with Parkinson's disease as it provides an on-demand, inhalable form of levodopa, offering an effective way to manage “OFF” episodes. This method of delivery, achievable through the innovative and proprietary technology platform, ARCUS®, is especially valuable for people who need rapid relief from their symptoms, which cannot be achieved reliably through oral intake.
(F)AMPYRA is the first medication approved for improving walking in patients with MS, demonstrated by an improved walking ability.
“Expanding the portfolio with INBRIJA, including plans for worldwide product roll-out, and (F)AMPYRA allows Merz Therapeutics the opportunity to leverage its experience in the specialty neurology space to serve even more patients living with neurological disorders and support the physicians who treat them,” said Stefan Albrecht, Chief Scientific and Medical Officer. “Because these treatments complement the company’s product portfolio and distribution system, we are well positioned to support patients who depend on these products seamlessly.”
About INBRIJA
INBRIJA® is an inhaled prescription levodopa medicine used to treat the return of Parkinson’s symptoms (known as “OFF” episodes) in people with Parkinson’s disease who are treated with carbidopa/levodopa medicines. It does not replace the regular carbidopa/levodopa medicines. INBRIJA is not to be used by people with Parkinson’s disease who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine, within the last 2 weeks. The most common side effects of INBRIJA are cough, upper respiratory tract infection, nausea and change in the color of saliva or spit.
About FAMPYRA
FAMPYRA® is a prolonged-release (sustained release) tablet formulation of the drug fampridine (4-aminopyridine, 4-AP or dalfampridine). FAMPYRA is indicated in the European Union for the improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS 4-7). In clinical trials, the highest incidence of adverse reactions identified with FAMPYRA given at the recommended dose was urinary tract infection. Other adverse drug reactions identified were mainly divided between neurological disorders such as insomnia, balance disorder, dizziness, paraesthesia and headache, and gastrointestinal disorders including nausea, dyspepsia and constipation. In post-marketing experience, there have been reports of seizure. Please see FAMPYRA EPAR for more information.
About AMPYRA
AMPYRA® is an extended-release tablet formulation of dalfampridine (4-aminopyridine, 4-AP or fampridine). AMPYRA is a potassium channel blocker approved as a treatment to help improve walking in adults with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. The most common side effects for AMPYRA in MS patients were urinary tract infection; trouble sleeping; dizziness; headache; nausea; weakness; back pain; problems with balance; multiple sclerosis relapse; burning, tingling, or itching of your skin; irritation in your nose and throat; constipation; indigestion; and pain in your throat. Please see the AMPYRA Patient Medication Guide for more information.
About Merz Therapeutics
Merz Therapeutics is dedicated to improving the lives of patients around the world. With its relentless research, development and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease and other health conditions that severely impact patients’ quality of life.
Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 115 years to developing innovations that serve unmet patient and customer needs.
Please visit www.merztherapeutics.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240710459851/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacsun Successfully Implements Manhattan Active® Point of Sale, Unifying Commerce and Cutting Checkout Times19.11.2025 09:00:00 CET | Press release
Manhattan Associates Inc. (NASDAQ: MANH) today announced that Pacsun, a leading youth fashion retailer, has successfully deployed Manhattan Active® Point of Sale (POS), a cloud-native in-store sales and service solution that empowers associates to merge digital convenience with personalised retailing. Following a five-month project start to pilot phase, Pacsun rolled out Manhattan's POS solution across 300 plus stores in just eight weeks. Mobile checkout capabilities eased long in-store lines, while unified inventory management, powered by RFID integration, supported seamless fulfilment across Instagram, Amazon, TikTok and Pacsun’s own channels. During peak holiday season, Pacsun achieved record breaking revenue and streamlined operations, with 40% of online orders being fulfilled via stores, optimising inventory proximity, labour capacity and shipping costs that reduced logistics expenses by 25%. Stores are now critical drivers of retail differentiation, with industry research showing
Frontgrade Gaisler and DELTATEC Enable Advanced Space Computing Across Multiple Missions19.11.2025 09:00:00 CET | Press release
Frontgrade™ Gaisler Technologies a leading provider of high-reliability electronic solutions for space and national security missions, and DELTATEC,a very high-level design house specialized in advanced technologies are pleased to celebrate their successful collaboration in delivering high-performance computing solutions for space applications, with the GR712RC dual-core microprocessor at the heart of several flight-proven systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119011567/en/ The GR712RC, developed by Frontgrade Gaisler and based on the fault-tolerant LEON3FT architecture, has been integrated into multiple Data Handling System (DHS) units designed by DELTATEC. These include one Payload Data Handling Unit (PDHU) and two On-Board Computers (OBCs) currently operating aboard ESA’s eSAIL mission, launched into Low Earth Orbit (LEO) in September 2020. Moreover, DELTATEC recently delivered the Flight Model of the
AGC Biologics and Repair Biotechnologies Partner on Novel mRNA Therapeutic to Combat the Leading Cause of Human Mortality19.11.2025 09:00:00 CET | Press release
Partnership leverages AGC Biologics’ cost-effective and dependable cGMP mRNA and LNP capabilities AGC Biologics today announced it is partnering with Repair Biotechnologies to tackle one of the world's most persistent health challenges and cause of mortality. The collaboration will focus on developing and manufacturing a novel mRNA therapy to rapidly stabilize and reduce the size of atherosclerotic plaques in major blood vessels. Rupture of unstable plaque and subsequent heart attack or stroke is the leading cause of death, accounting for 27% of all human mortality. “Developing a novel mRNA therapeutic as a part of the vital goal of curing atherosclerotic cardiovascular disease is a complex task, and robust manufacturing is critical to our progress,” said Reason, CEO and co-founder, Repair Biotechnologies. “We chose AGC Biologics because they have mastered the entire production chain for therapeutics of this class, eliminating critical risks and delays to provide a fast and reliable pa
Wasabi Introduces High-Performance Class and Expands into Silicon Valley to Take on AI’s Rising Data Storage Costs19.11.2025 09:00:00 CET | Press release
Wasabi Fire and AI-ready San Jose region give organizations a powerful alternative to hyperscalers, combining speed, simplicity, and predictable pricing for AI workloads Wasabi Technologies, the Hot Cloud Storage company, expanded further into artificial intelligence with the unveiling of Wasabi Fire, a high-performance storage class that supports AI workloads, available beginning in early 2026. Wasabi has also opened a new storage region in San Jose, Calif., as part of its relationship with IBM Cloud. The milestones reinforce Wasabi’s push to expand its role in AI infrastructure as demand for scalable, high-performance and cost-efficient cloud storage accelerates. “Object storage is the backbone of AI, but customers shouldn’t have to choose between speed and cost,” said David Friend, co-founder and CEO of Wasabi Technologies. “With Wasabi Fire, we’re delivering NVMe performance at disruptive prices, allowing organizations to cost-effectively store the critical data needed to train AI.
Aqara's Next-Generation Radiator Thermostat Delivers Smarter, Greener Heating to European Homes19.11.2025 09:00:00 CET | Press release
Aqara, a global leader and pioneer in IoT, today announces the availability of its Radiator Thermostat W600, first unveiled at IFA 2025. Boasting smart features like convenient temperature control, automated climate regulation, and seamless interoperability across Matter ecosystems via Thread/Zigbee protocol, the W600 transforms traditional radiators into intelligent, energy-efficient heating systems that not only enhance comfort but also help reduce energy bills. Designed for sustainable living, the Radiator Thermostat W600 delivers energy savings by minimizing heating in unoccupied areas. Instead of heating the whole home, users can schedule temperature adjustments for individual rooms, with up to 7 time periods per day, aligning with daily routines. Furthermore, these thermostatic radiator valves (TRV) can regulate indoor temperature based on environmental and behavioral triggers like room occupancy and geofencing, allowing for a heating system that adapts to real-time usage and occ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom